Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 8, 2016, Pages 1511-1520

  Manfredi, Angelo A ^a   Baldini, Mattia ^a   Camera, Marina ^b,c   Baldissera, Elena ^a   Brambilla, Marta ^c   Peretti, Giuseppe ^d,e   Maseri, Attilio ^a   Rovere Querini, Patrizia ^a   Tremoli, Elena ^b,c   Sabbadini, Maria Grazia ^a   Maugeri, Norma ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CENTRO CARDIOLOGICO MONZINO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Anti TNF; Atherosclerosis; Cardiovascular Disease; Rheumatoid Arthritis; TNF Alpha

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; PADGEM PROTEIN; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; RECOMBINANT PROTEIN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CELL ADHESION; DRUG EFFECTS; LEUKOCYTE; LEUKOCYTE COUNT; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CELL ADHESION; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962144793     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208442     Document Type: Article

References (44)

1. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 2011;70:8-14.
2. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
3. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010;69:1996-2001.
4. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015;11:390-400.
5. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-Analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70.
6. Ajeganova S, de Faire U, Jogestrand T, et al. Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis-An Inception Cohort Study. J Rheumatol 2012;39:1146-54.
7. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004;110:1774-9.
8. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014;53:2143-54.
9. Bergström U, Jacobsson LT, Turesson C. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden. Rheumatology (Oxford) 2009;48:1600-5.
10. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
11. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology (Oxford) 2011;50:518-31.
12. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-Analysis. Ann Rheum Dis 2015;74:480-9.
13. Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. Thromb Res 2013;131:191-7.
14. Maugeri N, Manfredi AA. Tissue factor expressed by neutrophils: Another piece in the vascular inflammation puzzle. Semin Thromb Hemost 2015;41:728-36.
15. Maugeri N, Brambilla M, Camera M, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 2006;4:1323-30.
16. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-Tissue factor cross-Talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177:4794-802.
17. Kambas K, Markiewski MM, Pneumatikos IA, et al. C5a and TNF-α up-regulate the expression of tissue factor in intra-Alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008;180:7368-75.
18. Semeraro F, Ammollo CT, Semeraro N, et al. Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 2009;94:819-26.
19. Camera M, Frigerio M, Toschi V, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol 2003;23:1690-6.
20. Camera M, Toschi V, Brambilla M, et al. The role of tissue factor in atherothrombosis and coronary artery disease: insights into platelet tissue factor. Semin Thromb Hemost 2015;41:737-46.
21. Celi A, Lorenzet R, Furie BC, et al. Microparticles and a P-selectin-mediated pathway of blood coagulation. Dis Markers 2004;20:347-52.
22. Yaron M, Djaldetti M. Platelets in synovial fluid. Arthritis Rheum 1978;21:607-8.
23. Knijff-Dutmer EA, Koerts J, Nieuwland R, et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002;46:1498-503.
24. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327:580-3.
25. Boilard E, Blanco P, Nigrovic PA. Platelets: Active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012;8:534-42.
26. Gasparyan AY, Ayvazyan L, Pretorius E, et al. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des 2014;20:552-66.
27. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
29. Prevoo ML, van t Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
30. Maugeri N, Rovere-Querini P, Evangelista V, et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS ONE 2012;7:e39484.
31. Maugeri N, Rovere-Querini P, Baldini M, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: A candidate for microvessel injury in sytemic sclerosis. Antioxid Redox Signal 2014;20:1060-74.
32. Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-7.
33. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-489c.
34. Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007;34:937-42.
35. Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-Tumor necrosis factor-Alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473-80.
36. Wang JG, Manly D, Kirchhofer D, et al. Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice. J Thromb Haemost 2009;7:1092-8.
37. Pamuk GE, Vural O, Turgut B, et al. Increased platelet activation markers in rheumatoid arthritis: Are they related with subclinical atherosclerosis? Platelets 2008;19:146-54.
38. Schmitt-Sody M, Metz P, Gottschalk O, et al. Platelet P-selectin is significantly involved in leukocyte-endothelial cell interaction in murine antigen-induced arthritis. Platelets 2007;18:365-72.
39. Schmitt-Sody M, Metz P, Klose A, et al. In vivo interactions of platelets and leucocytes with the endothelium in murine antigen-induced arthritis: The role of P-selectin. Scand J Rheumatol 2007;36:311-19.
40. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007;21:99-111.
41. Limb GA, Webster L, Soomro H, et al. Platelet expression of tumour necrosis factor-Alpha (TNF-Alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol 1999;118:213-18.
42. Pignatelli P, Cangemi R, Celestini A, et al. Tumour necrosis factor alpha upregulates platelet CD40L in patients with heart failure. Cardiovasc Res 2008;78:515-22.
43. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor in infectious disease. J Pathol 2013;230:132-47.
44. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20.